STAT3 and renal cell carcinoma: LncRNA-SRLR induces the IL-6/STAT3 axis to induce sorafenib resistance in RCC, and lncRNA-SRLR inhibition sensitizes nonresponsive RCC cells to sorafenib treatment in vitro.